U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H19ClFN7
Molecular Weight 387.842
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FALNIDAMOL

SMILES

CN1CCC(CC1)NC2=NC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=N2

InChI

InChIKey=FTFRZXFNZVCRSK-UHFFFAOYSA-N
InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)

HIDE SMILES / InChI
Falnidamol is an epidermal growth factor receptor inhibitor, developed by Boehringer Ingelheim. Falnidamol demonstrated anticancer activity in vitro. The phase I trial was discontinued due to a dose-limiting increase of liver enzymes, low bioavailability of the drug and the detection of a pharmacologically inactive metabolite.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00533|||Q9GZX1
Gene ID: 1956.0
Gene Symbol: EGFR
Target Organism: Homo sapiens (Human)
3.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [IC50 25.929 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
2004 Nov
Patents

Sample Use Guides

In a phase I study, patients received falnidamol orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 150 mg.
Route of Administration: Oral
T47D cells were treated with falnidamol at 0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM for 1 h. 3 uM of the drug was sufficient to block signaling by TGF-alpha. 10 uM falnidamol blocked ErbB2 activity efficiently.
Name Type Language
FALNIDAMOL
INN   WHO-DD  
INN  
Official Name English
BIBX1382
Common Name English
Falnidamol [WHO-DD]
Common Name English
8-(3-CHLORO-4-FLUOROANILINO)-2-((1-METHYL-4-PIPERIDYL)AMINO)PYRIMIDO(5,4-D)PYRIMIDINE
Systematic Name English
BIBX-1382
Code English
falnidamol [INN]
Common Name English
BIBX 1382
Code English
Classification Tree Code System Code
NCI_THESAURUS C2167
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
Code System Code Type Description
SMS_ID
100000127711
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
CAS
196612-93-8
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
EVMPD
SUB33798
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
FDA UNII
0MU316797D
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
INN
7857
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
DRUG BANK
DB12966
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
PUBCHEM
6918508
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
NCI_THESAURUS
C80868
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL258940
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID0048399
Created by admin on Fri Dec 15 16:17:42 GMT 2023 , Edited by admin on Fri Dec 15 16:17:42 GMT 2023
PRIMARY